Zacks Research Forecasts Reduced Earnings for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Investment analysts at Zacks Research reduced their FY2026 EPS estimates for shares of Avanos Medical in a research report issued to clients and investors on Wednesday, March 18th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.07 for the year, down from their previous estimate of $1.08. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q1 2027 earnings at $0.27 EPS, Q3 2027 earnings at $0.25 EPS, Q4 2027 earnings at $0.26 EPS and FY2028 earnings at $0.73 EPS.

Several other equities research analysts have also recently weighed in on the company. Wall Street Zen cut Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

Avanos Medical Stock Down 3.0%

AVNS opened at $13.05 on Friday. Avanos Medical has a 12 month low of $9.30 and a 12 month high of $15.68. The company has a current ratio of 2.15, a quick ratio of 1.26 and a debt-to-equity ratio of 0.12. The business’s 50-day moving average price is $13.66 and its 200-day moving average price is $12.32. The company has a market cap of $606.98 million, a P/E ratio of -8.26 and a beta of 1.07.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The business had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.70 million. During the same period in the previous year, the firm posted $0.43 earnings per share. The firm’s revenue for the quarter was up .7% on a year-over-year basis. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS.

Hedge Funds Weigh In On Avanos Medical

Several hedge funds and other institutional investors have recently modified their holdings of AVNS. EverSource Wealth Advisors LLC grew its position in shares of Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock worth $28,000 after buying an additional 1,423 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of Avanos Medical by 49.7% during the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock valued at $31,000 after acquiring an additional 894 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after acquiring an additional 2,307 shares during the period. Wexford Capital LP purchased a new stake in Avanos Medical in the third quarter worth $70,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Avanos Medical by 433.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after acquiring an additional 5,083 shares in the last quarter. 95.17% of the stock is owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.